← Back

Jenkem Technology Co Ltd

Jenkem Technology Co., Ltd. is a China-based company that researches, develops, produces, and sells medical and pharmaceutical polyethylene glycol (PEG) and its derivatives. Its product portfolio includes high molecular weight PEG derivatives, monodisperse PEG products, click chemistry reagents, lipid nanoparticle delivery system accessories, PEG linkers, PEG medical devices, PEG standards, block copolymers, and long-acting polypeptide fatty acid side chains. The company also offers Silkrose injectable cross-linked sodium hyaluronate gel for correcting nasolabial folds, as well as technical services such as synthetic method development and PEGylation technology services. Incorporated in 2001, it is headquartered in Beijing, China.

Price · split & dividend adjusted
News & notes moving 688356.CG
China
Semiconductors▼

YMTC Holdings' STAR Market IPO application accepted, plans to raise 33 billion yuan

YMTC Holdings' application for an initial public offering and listing on the STAR Market has been accepted by the Shanghai Stock Exchange, with a planned fundraising amount of 33 billion yuan. The sponsors are CITIC Securities and China Securities. The prospectus shows that the company's profitability has improved rapidly since turning a profit in 2024. From January to March 2026, it achieved operating revenue of 47.042 billion yuan and net profit attributable to the parent company of 33.379 billion yuan. According to TrendForce data, during the same period, the company ranked third globally and first in China among NAND Flash manufacturers by both sales revenue and shipment volume. In addition, CanSino Biologics announced that it is developing mRNA preventive vaccines and therapeutic biological products. JenKem Technology clarified that it has not directly supplied LNP core raw materials to Moderna. Several other STAR Market companies, including Sinovac Biotech, Hwatsing Technology, and UCloud, disclosed their semi-annual results.
Jenkem Technol… ▼Cansino Biolog…
Semiconductors ▲
About megatrends
Semiconductors › Memory — DRAM, NAND & HBM ▲Capital
688356.CG · Demand · Negative Clarified it has not directly supplied LNP core raw materials to Moderna, potentially reducing expected demand.
688185.CG · Technology · Neutral Developing mRNA preventive vaccines and therapeutic biological products, but no specific progress or impact details.
Read original ↗
CLS·45dRead more →
United StatesChina
Biotech & Genomic Medicine▲

Moderna shares surge nearly 180%, chemical pharmaceutical concept rallies strongly

On August 20, the chemical pharmaceutical concept rose 4.21% intraday, with JenKem Technology, Lummy Pharmaceutical, Youcare Pharmaceutical and other constituent stocks leading gains. In news, overnight US stock Moderna shares surged nearly 180%, as Merck and Moderna announced the first Phase III clinical trial of their jointly developed mRNA personalized cancer vaccine intismeran autogene achieved preliminary positive results. A China Merchants Securities research report noted that in 2026, the chemical pharmaceutical industry is in a gear-shift period of concentrated clearing of legacy risks and accelerated realization of innovation achievements. Leading companies, relying on technology platform upgrades, have entered late-stage clinical and early commercialization phases. It recommends focusing on differentiated leaders with complex formulation platforms and global business development capabilities.
MRNA ▲MRK ▲Jenkem Technol… ▲
Biotech & Genomic Medicine ▲
About megatrends
Biotech & Genomic Medicine › mRNA Platforms ▲Technology
MRNA · Technology · Positive Moderna's stock surged nearly 180% on positive Phase III trial results for its mRNA cancer vaccine.
MRK · Technology · Positive Merck and Moderna announced positive Phase III results for their jointly developed mRNA cancer vaccine.
688356.CG · Technology · Positive As a chemical pharmaceutical company, benefits from sector rally driven by positive mRNA cancer vaccine trial results.
Read original ↗
南方财经网·46dRead more →
© 2026 MarketDXAsset